Immunome, Inc. IMNM
17.18 USD -0.43 (-2.44%)
Regular-session close
17.18 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
16.78 Day range 18.16
16.41 52-week range 30.06
- YTD
- -20.02%
- 1 year
- -5.24%
News
seekingalpha.com Immunome: De-Risked With The FDA, With An Admirably Deep Clinical Bench I maintain a Buy on Immunome, Inc.: its $2.1 billion market cap leaves upside versus the Springworks acquisition valuation. Varegacestat's phase 3 progression-free survival hazard ratio was 0.16; the…
benzinga.com Immunome Analysts Cut Their Forecasts After Q3 Results Immunome Inc (NASDAQ:IMNM) on Monday posted a wider-than-expected loss for the third quarter.
benzinga.com Immunome Analysts Cut Their Forecasts After Q3 Results Immunome posted a wider Q3 loss than expected, shares fell 4.6%, and analysts cut price targets despite oncology pipeline progress.benzinga.com Stifel Maintains Hold on Immunome, Lowers Price Target to $23 Stifel analyst Dara Azar maintains Immunome (NASDAQ:IMNM) with a Hold and lowers the price target from $24 to $23.
benzinga.com Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30 Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.
businesswire.com Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced…
businesswire.com Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies,…
zacks.com Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know The consensus price target hints at a 74% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
zacks.com 4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.
businesswire.com Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today…benzinga.com Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary…
businesswire.com Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today…benzinga.com Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.
benzinga.com Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026 Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48Four presentations build on the previously reported Phase 3 RINGSIDE…
businesswire.com Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today…
businesswire.com Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer…
businesswire.com Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today…
businesswire.com Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer…
businesswire.com Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today…
marketbeat.com argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients…
globenewswire.com argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained…
seekingalpha.com Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat's NDA and a PDUFA date set for April 2027. The company's pipeline is diversified,…
businesswire.com Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial…
businesswire.com Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced…
defenseworld.net Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and…
businesswire.com Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the…
